Candel Therapeutics Long Term Debt

Candel Therapeutics (CADL) currently reports a long-term debt of $49M as of June 2026. That compares with $1M in the prior-year period — up 4603.4% year over year. Use the charts on this page to explore Candel Therapeutics's long-term debt history and peer comparisons.

Candel Therapeutics's long-term debt increased from $1M to $49M — a 4603.4% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Candel Therapeutics reported $49M in long-term debt as of June 2026. That compares with $1M in the prior-year period — up 4603.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $49M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Candel Therapeutics, and consider following CADL for alerts when major investors trade the stock.

Candel Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $49M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CADL with unrelated industries.